Pandion Therapeutics Inc (PAND) Stock Price, Forecast & Analysis

NASDAQ:PAND

60.05
+0.13 (+0.22%)
At close: Mar 31, 2021
60.05
0 (0%)
After Hours: 3/31/2021, 8:12:53 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

PAND Key Statistics, Chart & Performance

Key Statistics
Market Cap1.77B
Revenue(TTM)8.78M
Net Income(TTM)-38.10M
Shares29.52M
FloatN/A
52 Week High62.9
52 Week Low10.28
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.81
PEN/A
Fwd PEN/A
Earnings (Next)03-11
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
PAND short term performance overview.The bars show the price performance of PAND in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300 400

PAND long term performance overview.The bars show the price performance of PAND in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of PAND is 60.05 null. In the past month the price decreased by -2.56%.

Pandion Therapeutics Inc / PAND Daily stock chart

PAND Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to PAND.


Chartmill TA Rating
Chartmill Setup Rating
PAND Full Technical Analysis Report

PAND Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to PAND. PAND may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PAND Full Fundamental Analysis Report

PAND Financial Highlights

Over the last trailing twelve months PAND reported a non-GAAP Earnings per Share(EPS) of -2.8116. The EPS increased by 86.71% compared to the year before.


Industry RankSector Rank
PM (TTM) -434.05%
ROA N/A
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)86.71%
Revenue 1Y (TTM)807.86%
PAND financials

PAND Forecast & Estimates


Analysts
Analysts73.4
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
PAND Analyst EstimatesPAND Analyst Ratings

PAND Ownership

Ownership
Inst OwnersN/A
Ins Owners19.35%
Short Float %N/A
Short RatioN/A
PAND Ownership

About PAND

Company Profile

Pandion Therapeutics Inc. is a biotechnology company. It focuses on developing modular proteins, antibodies and bispecifics for the treatment of autoimmune and inflammatory diseases. Pandion Therapeutics Inc. is based in North Cambridge, United States.

Company Info

Pandion Therapeutics Inc

134 COOLIDGE AVENUE 2ND FLOOR

WATERTOWN MA 02472

CEO: Rahul Kakkar

Phone: 617-393-5925

Pandion Therapeutics Inc / PAND FAQ

What does PAND do?

Pandion Therapeutics Inc. is a biotechnology company. It focuses on developing modular proteins, antibodies and bispecifics for the treatment of autoimmune and inflammatory diseases. Pandion Therapeutics Inc. is based in North Cambridge, United States.


Can you provide the latest stock price for Pandion Therapeutics Inc?

The current stock price of PAND is 60.05 null. The price increased by 0.22% in the last trading session.


Does PAND stock pay dividends?

PAND does not pay a dividend.


What is the ChartMill technical and fundamental rating of PAND stock?

PAND has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is Pandion Therapeutics Inc worth?

Pandion Therapeutics Inc (PAND) has a market capitalization of 1.77B null. This makes PAND a Small Cap stock.